Evidence map›Paper›PMID 34748168›Full record

ReviewEndocrine2022

Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.

Michele Klain, Julien Hadoux, Carmela Nappi, Monica Finessi, Raffaele Ambrosio, Martin Schlumberger, Alberto Cuocolo, Désirée Deandreis, Domenico Salvatore

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Exploring the value of sentinel lymph node PET/CT detection in thyroid carcinoma.European journal of nuclear medicine and molecular imaging · 2024
    Article
  9. The Role ofMolecular imaging and radionuclide therapy · 2023
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Michele KlainDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.
Julien HadouxDepartment of Endocrine Oncology and Nuclear Medicine, Gustave Roussy and University Paris-Saclay, Villejuif, France.
Carmela NappiDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.
Monica FinessiDepartment of Medical Science, Nuclear Medicine Division, University of Turin, Turin, Italy.
Raffaele AmbrosioIRCCS SDN, Naples, Italy.
Martin SchlumbergerDepartment of Endocrine Oncology and Nuclear Medicine, Gustave Roussy and University Paris-Saclay, Villejuif, France.
Alberto CuocoloDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.
Désirée DeandreisDepartment of Medical Science, Nuclear Medicine Division, University of Turin, Turin, Italy.
Domenico SalvatoreDepartment of Public Health, University of Naples "Federico II", Naples, Italy. domsalva@unina.it.
University of Naples Federico II · ITInstitut Gustave Roussy · FRUniversity of Turin · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca 2017YTWKWH
6 · The paper itself

Abstract

purposeMedullary thyroid carcinoma (MTC) originates from thyroid parafollicular C-cells and represents <5% of all thyroid cancers. Serum Calcitonin (CTn) is considered the most sensitive marker of persistent or recurrent disease and is measured in association to CEA. According to the American Thyroid Association (ATA) guidelines, following initial surgery when CTn level remains below 150 pg/mL, follow-up may rely on repeated serum marker determinations and on neck ultrasonography (US). When CTn level exceeds 150 pg/ml, additional imaging is required. In this review, we provide an overview of available imaging tools to monitor MTC course and propose an effective imaging strategy for MTC patients according to their clinical situation.

methodsA literature search focusing on available imaging tools to monitor MTC provided the currently available information for this review. Recent evidence-based reports and reviews were considered as priority over older evidence.

resultsFor MTC patients with detectable CTn levels and disease recurrence, PET/CT imaging with

conclusionThe role of imaging in MTC patients improved, especially with the use of

Indexed as

Carcinoma, NeuroendocrineThyroid NeoplasmsBiomarkersHumansPositron Emission Tomography Computed TomographyProspective StudiesBiomarkersImagingMedullary Thyroid CarcinomaMTCPET/CTUltrasonography

Identifiers

PMID34748168
OpenAlexW3213122734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.